Search the Newsreel

Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating

Truist has increased its price target for Progyny (PGNY) from $33 to $36, while reiterating a Buy rating on the stock. This adjustment follows Progyny's Q2 2026 earnings report, where the company exceeded revenue estimates. Progyny, a benefit management company specializing in fertility and …

The 5 Most Interesting Analyst Questions From Progyny’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From Progyny's Q2 Earnings Call Progyny's second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expectations. CEO Peter Anevski attributed the quarter's growth to continued demand …

PGNY Maintains Rating by Barclays -- Price Target Lowered to $30

Barclays has maintained an Equal-Weight rating on Progyny (PGNY) but lowered its price target to $30 from $34. Despite this, Progyny is considered undervalued by GuruFocus with a GF Value™ of $28.56 against its current price of $26.55, and boasts a strong GF Score™ …

Progyny Drops 5.4% Amid Sector-Wide Selling

Progyny, Inc. experienced a 5.4% decline, closing at $26.34, as part of a sector-wide selloff affecting healthcare plan providers. The drop, accompanied by similar losses in peer companies like ALHC and MRDH, suggests broader investor repositioning rather than company-specific news. Investors are advised to …

Progyny, Inc. $PGNY Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC significantly reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 84.1% in the first quarter, selling over 200,000 shares. Despite this, institutional investors collectively hold 94.93% of the company's stock, and analyst sentiment remains positive with a "Moderate Buy" consensus and …

Progyny (PGNY) Stock May Still Trade At A Discount As Earnings Hold Up

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Progyny stock has delivered a 38.8% decline over the past five years, even though the valuation checks currently suggest the shares may be pricing …

Progyny (PGNY) Faces A Valuation Test After Earnings, Guidance, And A Buyback

PGNY Q2 CY2026 Deep Dive: Seasonality and Guidance Weigh on Positive Underlying Performance

PGNY Q2 CY2026 Deep Dive: Seasonality and Guidance Weigh on Positive Underlying Performance Fertility benefits company Progyny (NASDAQ:PGNY) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 5.3% year on year to $350.5 million. On the other hand, next quarter's …

Progyny (PGNY) Stock Looks Fairly Priced With Limited Margin Of Safety

Progyny (PGNY) Stock Sinks As Guidance Jitters Clash With Margin Strength

Progyny, Inc. Stock 12‑Month Price Target Cut to $33.82, Implies 12% Upside

Progyny, Inc.'s average stock price target has been reduced to $33.82 from $34 by 11 analysts, with individual forecasts ranging from $27 to $40 per share. This updated target suggests a potential 12% upside based on the Aug. 6 closing price. The consensus rating …

Progyny, Inc. 2026: Revenue $350.51M, EPS $0.34— 10-Q Summary

Progyny, Inc. reported strong second-quarter 2026 results, with revenue reaching $350.51 million and diluted EPS of $0.34, showcasing modest top-line growth and significant profitability improvement year-over-year. The company expanded its client base to over 600, covering approximately 7.2 million lives, and saw improved gross …

Progyny Posts Record Q2 Results, Expands Client Base

Progyny reported record second-quarter 2026 results with revenue of $350.5 million, up 5.3% year-over-year, and a 13% increase in gross profit to $89.3 million, despite losing a large client. The company also saw net income rise to $28.1 million and adjusted EBITDA to $62.1 …

Why Progyny (PGNY) Shares Are Sliding Today

Progyny's shares dropped by 4.5% after the company issued a weaker-than-expected forecast for the upcoming quarter and lowered its full-year revenue and EBITDA guidance, despite beating second-quarter earnings estimates. This disappointing outlook overshadowed strong Q2 results and previous analyst upgrades, leading to a significant …

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny's stock initially dropped by 6% after its second-quarter earnings report, despite sales rising 5% and adjusted earnings per share increasing by 15%, both exceeding Wall Street expectations. The market reacted negatively to management's conservative Q3 revenue growth guidance of 7% to 11%. However, …

Progyny CEO’s Aug. 11 Boston session will have a live audiocast

Progyny, Inc. (Nasdaq: PGNY) announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be accessible via …

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be accessible via a live audiocast and replay on Progyny’s investor relations website. Progyny …

Higher Q2 profit and share buybacks at Progyny (NASDAQ: PGNY)

Progyny, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PGNY) 2026-08-07

Progyny, Inc. has published its Q2 2026 earnings call presentation. The company reported EPS of $0.55, beating estimates by $0.03, and revenue of $350.51 million, surpassing expectations by $1.86 million, representing a 5.30% year-over-year increase. This article provides access to the slide deck presented …

Progyny Inc (PGNY) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Amid Strategic ...

Progyny Inc (PGNY) reported record revenue, gross profit, and adjusted EBITDA for Q2 2026, with revenue increasing 5.3% year-over-year. The company provided full-year 2026 guidance, projecting revenue between $1.36 billion and $1.385 billion, and reaffirmed strong selling season momentum and client retention. Despite a …

Progyny Q2 2026 earnings: Margin expansion lifts profit faster than revenue

Progyny (Nasdaq: PGNY) reported Q2 2026 revenue of $350.5 million, a 5.3% year-over-year increase, and diluted EPS of $0.34, significantly up from $0.19 in Q2 2025. The company's profit growth outpaced revenue growth due to gross-margin expansion and lower stock-based compensation, despite a decline …

Earnings call transcript: Progyny beats Q2 2026 estimates, shares sink after hours

Progyny reported strong Q2 2026 results, beating adjusted EPS and revenue estimates with $0.55 per share and $350.51 million, respectively. Despite record financial performance, shares fell 15.59% in after-hours trading due to management's comments on a more pronounced summer slowdown impacting Q3 guidance. The …

Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates

Progyny’s (NASDAQ:PGNY) Q2 CY2026: Beats On Revenue But Stock Drops 10.2%

Progyny Non-GAAP EPS of $0.55 beats by $0.03, revenue of $350.5M beats by $1.85M

* Progyny press release [https://seekingalpha.com/pr/20610907-progyny-inc-announces-second-quarter-2026-results] (PGNY [https://seekingalpha.com/symbol/PGNY]): Q2 Non-GAAP EPS of $0.55 beats by $0.03. * Revenue of $350.5M (+5.3% Y/Y) beats by $1.85M. * Revenue was $350.5 million, a 5.3% increase as compared to the $332.9 million reported in the second quarter of …

Progyny, Inc. Announces Second Quarter 2026 Results

Progyny, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 5.3% to $350.5 million and net income rising to $28.1 million. The company reported record quarterly revenue, gross profit, and Adjusted EBITDA, driven by high member engagement and …

(PGNY) Progyny, Inc. Expects Q3 Revenue Range $335.0M - $345.0M

Progyny, Inc. (PGNY) announced its revenue expectations for the third quarter, projecting a range of $335.0 million to $345.0 million. This announcement follows their second-quarter earnings report, where the company posted revenues of $350.5 million, exceeding FactSet's estimate of $348.6 million, and an adjusted …

Pacer Advisors Inc. Buys 144,073 Shares of Progyny, Inc. $PGNY

Pacer Advisors Inc. significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 49.4% in the first quarter, acquiring 144,073 additional shares and bringing their total holdings to 435,558 shares valued at approximately $7.4 million. This comes as Progyny exceeded first-quarter earnings expectations with an …

FMR LLC and Abigail Johnson report 8.9% Progyny (PGNY) beneficial stake

FMR LLC and Abigail Johnson have reported a beneficial ownership stake of 8.9% in Progyny, Inc. (PGNY), according to a Schedule 13G/A SEC filing. This translates to 7,004,279.53 shares beneficially owned as of June 30, 2026. FMR LLC holds sole voting power over 7,003,929 …

Progyny (NASDAQ:PGNY) Shares Slide After Q2 Beat Overshadowed by Weak Guidance

Progyny (NASDAQ:PGNY) Issues Q3 2026 Earnings Guidance

Progyny, Inc. $PGNY Shares Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) during the first quarter, now holding 82,198 shares valued at approximately $1.4 million. This move is part of a broader trend of institutional investors owning a substantial 94.93% of the company. …

What To Expect From Progyny’s (PGNY) Q2 Earnings

Progyny (PGNY) is set to announce its Q2 earnings, with analysts expecting a 4.7% year-on-year revenue growth. The company previously beat revenue and EPS expectations last quarter. Investors are looking at peer performance, with CVS Health and Centene also reporting positive revenue growth in …